Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients with Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) with Documented Viral Infections with PIV, HMPV or RSV
Latest Information Update: 06 Nov 2024
Price :
$35 *
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications Metapneumovirus infections; Parainfluenza virus infections; Respiratory syncytial virus infections
- Focus Therapeutic Use
- Sponsors Pulmotect
- 06 Nov 2024 New trial record